NeuroSense shares are trading higher after the company reported results from a 12-month analysis of its PARADIGM Phase 2b study evaluating PrimeC in ALS patients, showing that disease progression was slowed by 36% compared to the placebo.
Portfolio Pulse from Benzinga Newsdesk
NeuroSense shares are trading higher following positive results from a 12-month analysis of its PARADIGM Phase 2b study. The study showed that PrimeC slowed ALS disease progression by 36% compared to the placebo.
July 01, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroSense shares are trading higher after the company reported that its PARADIGM Phase 2b study showed PrimeC slowed ALS disease progression by 36% compared to the placebo.
The positive results from the Phase 2b study are likely to boost investor confidence in NeuroSense's product pipeline, leading to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100